Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | ESR1 | P03372 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | PGR | P06401 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | STS | P08842 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7705120 | 1.00 | LMNA (0.77) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL6462059 | 1.00 | LMNA (0.77) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| Ethylene SCHEMBL11570544 | 0.87 | HSD17B1 (0.95) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL959954 | 0.87 | HSD17B1 (1.00) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL18658723 | 0.87 | HSD17B1 (1.00) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL4570835 | 0.87 | HSD17B1 (1.00) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL12441050 | 0.87 | HSD17B1 (1.00) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL15308964 | 0.87 | HSD17B1 (1.00) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL6671304 | 0.87 | LMNA (0.75) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL5677806 | 0.87 | HSD17B1 (1.00) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4940645-A | Imaging material employing photosensitive microcapsules containing tertiary amines as coinitiators | THE MEAD CORPORATION (US) | 1990-07-10 | — | — | US | claimed |
| US-20180117162-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-6352980-B1 | ADMINISTERING BY SPRAYING IN NOSE | PHERIN PHARMACEUTICALS, INC. | 2002-03-05 | — | — | US | disclosed |
| US-6331534-B1 | ADMINISTERING EFFECTIVE AMOUNT OF STEROID WITHIN NASAL PASSAGE OF INDIVIDUAL SUCH THAT IT BINDS SPECIFICALLY TO RECEPTORS ON SURFACE OF NASAL NEUROEPITHELIAL CELLS IN VOMERONASAL ORGAN | PHERIN PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| US-6117860-A | NASALLY ADMINISTERING STEROID WHICH BINDS TO A SPECIFIC NEUROEPITHELIAL RECEPTOR FOR ALLEVIATING PREMENSTRUAL TENSION AND ANXIETY | PHERIN PHARMACEUTICALS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6066627-A | ALTERING BLOOD CONCNETRATION OF LUTEINIZING HORMONE | PHERIN CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
| US-6057439-A | EPOXYSTEROIDS | PHERIN CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0783513-A4 | NOVEL ESTRENES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORP (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5994568-A | BIND TO NEUROEPITHELIAL RECEPTORS. | PHERIN CORPORATION (US) | 1999-11-30 | — | — | US | disclosed |
| US-5939570-A | Estrenes for inducing hypothalamic effects | PHERIN CORPORATION (US) | 1999-08-17 | — | — | US | disclosed |
| US-5925774-A | ESTRENE STEROIDS WHICH BIND TO NEUROEPITHELIAL RECEPTORS | PHERIN CORPORATION (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0924219-A2 | Novel estrenes for inducing hypothalamic effects | PHERIN CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0783513-A1 | NOVEL ESTRENES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5633392-A | STIMULANTS FOR AUTONOMIC NERVOUS SYSTEM; NOSE SPRAYING | PHERIN CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996010032-A1 | NOVEL ESTRENES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1996-04-04 | — | — | WO | disclosed |
| US-4977147-A | CONTRACEPTIVES, ANTITUMOR AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-12-11 | — | — | US | disclosed |
| EP-0320437-A2 | 17-Methylene and 17-ethylidene estratrienes having an oestrogenic activity | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117162-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | VDR, PROC, CYP24A1 | LMNA 2122/4885HSD17B1 1245/4885MAPT 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.